Literature DB >> 25803135

Prevalence of hereditary angioedema in untested first-degree blood relatives of known subjects with hereditary angioedema.

Marc A Riedl1, William R Lumry, Paula Busse, Howard Levy, Tamara Steele, Jeffrey Dayno, H Henry Li.   

Abstract

Hereditary angioedema (HAE) is a rare autosomal-dominant disease characterized by recurring attacks of nonpruritic, nonpitting edema caused by an inherited deficiency or dysfunction of C1 esterase inhibitor (C1 INH). Symptoms can present years before an accurate diagnosis is made. The objective of this study, the Angioedema Clinical Epidemiology Testing Initiative for the Study of Hereditary Angioedema, was to determine the prevalence and clinical manifestations of HAE in untested first-degree blood relatives of known patients with HAE. Patients with a confirmed diagnosis of HAE recruited first-degree relatives who had not been evaluated for HAE. Enrolled subjects underwent complement testing (C4, C1 INH antigen, and functional C1 INH). If the lab tests were abnormal, the enrolled subjects returned to the site for a follow-up visit and questionnaire. Overall, 31 patients with HAE and 46 first-degree relatives enrolled in the study. Of 46 enrolled relatives, 30 (65%) had lab test results that ruled out a diagnosis of HAE, two (4%) were categorized as "HAE not ruled out," and 14 (30%) were newly diagnosed with HAE. Of 14 newly diagnosed subjects, nine (64%) reported having experienced symptoms that may have been related to HAE, such as swelling in the throat, face, or extremities or abdominal pain. When reported, median age of symptom onset in these 14 subjects was nine years whereas newly diagnosed asymptomatic subjects had a median chronological age of six years. These 14 subjects reported a historic mean standard deviation rate of 2.51 (5.59) swelling episodes per month with a mean standard deviation duration of 1.6 (0.74) days. This study's findings reinforce the importance of testing family members of patients with HAE to detect this hereditary condition.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25803135      PMCID: PMC4405600          DOI: 10.2500/aap.2015.36.3833

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  14 in total

Review 1.  Clinical practice. Hereditary angioedema.

Authors:  Bruce L Zuraw
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

Review 2.  The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.

Authors:  Jerrold H Levy; Penrose S O'Donnell
Journal:  Expert Opin Investig Drugs       Date:  2006-09       Impact factor: 6.206

3.  Ecallantide for the treatment of acute attacks in hereditary angioedema.

Authors:  Marco Cicardi; Robyn J Levy; Donald L McNeil; H Henry Li; Albert L Sheffer; Marilyn Campion; Patrick T Horn; William E Pullman
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

4.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

Authors:  Marco Cicardi; Aleena Banerji; Francisco Bracho; Alejandro Malbrán; Bernd Rosenkranz; Marc Riedl; Konrad Bork; William Lumry; Werner Aberer; Henning Bier; Murat Bas; Jens Greve; Thomas K Hoffmann; Henriette Farkas; Avner Reshef; Bruce Ritchie; William Yang; Jürgen Grabbe; Shmuel Kivity; Wolfhart Kreuz; Robyn J Levy; Thomas Luger; Krystyna Obtulowicz; Peter Schmid-Grendelmeier; Christian Bull; Brigita Sitkauskiene; William B Smith; Elias Toubi; Sonja Werner; Suresh Anné; Janne Björkander; Laurence Bouillet; Enrico Cillari; David Hurewitz; Kraig W Jacobson; Constance H Katelaris; Marcus Maurer; Hans Merk; Jonathan A Bernstein; Conleth Feighery; Bernard Floccard; Gerald Gleich; Jacques Hébert; Martin Kaatz; Paul Keith; Charles H Kirkpatrick; David Langton; Ludovic Martin; Christiane Pichler; David Resnick; Duane Wombolt; Diego S Fernández Romero; Andrea Zanichelli; Francesco Arcoleo; Jochen Knolle; Irina Kravec; Liying Dong; Jens Zimmermann; Kimberly Rosen; Wing-Tze Fan
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

5.  Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.

Authors:  Bruce L Zuraw; Paula J Busse; Martha White; Joshua Jacobs; William Lumry; James Baker; Timothy Craig; J Andrew Grant; David Hurewitz; Leonard Bielory; William E Cartwright; Majed Koleilat; Walter Ryan; Oren Schaefer; Michael Manning; Pragnesh Patel; Jonathan A Bernstein; Roger A Friedman; Robert Wilkinson; David Tanner; Gary Kohler; Glenne Gunther; Robyn Levy; James McClellan; Joseph Redhead; David Guss; Eugene Heyman; Brent A Blumenstein; Ira Kalfus; Michael M Frank
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

Review 6.  C1 inhibitor deficiency: consensus document.

Authors:  M M Gompels; R J Lock; M Abinun; C A Bethune; G Davies; C Grattan; A C Fay; H J Longhurst; L Morrison; A Price; M Price; D Watters
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

7.  Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?

Authors:  Michael L Lunn; Carah B Santos; Timothy J Craig
Journal:  Ann Allergy Asthma Immunol       Date:  2010-03       Impact factor: 6.347

8.  Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain.

Authors:  Olga Roche; Alvaro Blanch; Teresa Caballero; Noelia Sastre; Daniel Callejo; Margarita López-Trascasa
Journal:  Ann Allergy Asthma Immunol       Date:  2005-04       Impact factor: 6.347

9.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.

Authors:  Timothy J Craig; Robyn J Levy; Richard L Wasserman; Againdra K Bewtra; David Hurewitz; Krystyna Obtułowicz; Avner Reshef; Bruce Ritchie; Dumitru Moldovan; Todor Shirov; Vesna Grivcheva-Panovska; Peter C Kiessling; Heinz-Otto Keinecke; Jonathan A Bernstein
Journal:  J Allergy Clin Immunol       Date:  2009-09-19       Impact factor: 10.793

10.  Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe.

Authors:  Andrea Zanichelli; Markus Magerl; Hilary Longhurst; Vincent Fabien; Marcus Maurer
Journal:  Allergy Asthma Clin Immunol       Date:  2013-08-12       Impact factor: 3.406

View more
  4 in total

1.  Insights, strategies, asthma and allergy risk factors, and the allergist/immunologist: Challenges to be met and promises to keep!

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2016 Jan-Feb       Impact factor: 2.587

2.  Disorders for which the allergist-immunologist is particularly well-qualified to treat.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

3.  The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey of Canadian physicians and laboratories.

Authors:  Xavier Charest-Morin; Stephen Betschel; Rozita Borici-Mazi; Amin Kanani; Gina Lacuesta; Georges-Étienne Rivard; Eric Wagner; Susan Wasserman; Bill Yang; Christian Drouet
Journal:  Allergy Asthma Clin Immunol       Date:  2018-11-21       Impact factor: 3.406

4.  Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies.

Authors:  Emel Aygören-Pürsün; Markus Magerl; Andreas Maetzel; Marcus Maurer
Journal:  Orphanet J Rare Dis       Date:  2018-05-04       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.